Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
• Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2
• Recruitment of cohort 2 of Part A of TACTI-002, additional 19 patients, will begin shortly
• Recruitment of the first cohorts of parts B and C continues
• Data from the ongoing TACTI-002 Phase II clinical trial will be presented at the 34th Annual Meetingof the Society for Immunotherapy of Cancer (SITC) in November 2019
Great news !
2.6c here we set
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep expands Part A of TACTI-002 due to positive data
Ann: Immutep expands Part A of TACTI-002 due to positive data, page-3
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M |
Open | High | Low | Value | Volume |
32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 113721 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 0.330 |
3 | 89973 | 0.325 |
10 | 137686 | 0.320 |
5 | 75745 | 0.315 |
5 | 99268 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 113721 | 6 |
0.340 | 1320656 | 5 |
0.345 | 94973 | 3 |
0.350 | 509080 | 5 |
0.355 | 40082 | 2 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online